Stacy Assignment

Daniel Kim Study

Transcript

SPEAKER_00 0:01

All right. Good day everyone. My name is Stacey Bagallo. This is my ID. Alright. So today I will defend the use of a non-stimulant medication, specifically adamoxetine, for Daniel King, a 32-year-old marketing professional diagnosed with attention deficit hyperactivity disorder, predominantly inactive presentation, and comabid generalized anxiety disorder. Although stimulant medications are generally considered first-line pharmacologic treatment for ADHD, they are not the optimal choice for every patient. Individualized treatment requires clinicians to evaluate each patient's medical history, psychiatric comorbidities, functional impairment, and overall risk profile before selecting a medication. In Daniel's case, excuse me, his coexisting anxiety disorder and current treatment with searchuline make adamoxetine the safer and more appropriate therapeutic option. Daniel presents with persistent symptoms of inattention that have significantly affected his occupational performance. He reports difficulty organizing tasks, maintaining concentration, completing projects on time, and meeting workplace expectations. Although his anxiety has improved since starting Surchuline, 50 milligrams daily, he continues to experience excessive worry and difficulty sleeping. He denies any history of substance use and his concentration problems have become the primary factor threatening his job stability. My position is that adamoxetine should be initiated because it effectively treats ADHD symptoms while minimizing the risk of worsening Daniel's anxiety. Adamoxetine is a selective norepinephrine reuptake inhibitor that is approved by the U.S. Food and Drug Administration for treatment of ADHD in both children and adults. Unlike stimulant medications, adamoxetine increases norepinephrine activity without producing rapid increases in dopamine within the brain's reward pathways. As a result, it is virtually no abuse potential and is classified as a non-controlled medication. Although its onset of action is slower than stimulant medications, clinical improvement generally occurs within two to six weeks with improvement over several months. Current evidence supports adamoxetine as an effective treatment for adults with ADHD, particularly when psychiatric comorbidities are present. Daniel's generalized anxiety disorder is one of the most important considerations in selecting pharmacologic therapy. While stimulant medications effectively improve attention and executive functioning, they may increase central nervous system stimulations, resulting in worsening anxiety, nervousness, irritability, insomnia, tachycardia, and elevated blood pressure in susceptible individuals. For patients whose anxiety is already being managed successfully, introducing a stimulant may destabilize symptom control and reduce adherence to treatment. Research indicates that adamoxetine improves ADHD symptoms without consistently worsening anxiety disorders and may even produce modest improvements in anxiety as executive functioning and daily functioning show improvement. For Daniel, preserving control of his anxiety while treating the ADHD represents an important clinical priority. Another important consideration is Daniel's current use of serchuline. Adamoxetine may be safely prescribed with selective serotonin reuptake inhibitors when patients are monitored appropriately. Because adamoxetine is primarily metabolized by the cytochrone P450, specifically the CYP2D6 liver enzyme, clinicians should assess for potential drug interactions and adjust dosing if clinically indicated. Regular follow-up visits should include assessment of therapeutic response, adverse effects, blood pressure, heart rate, sleep quality, and overall functioning improvement. Patient education is also essential because adamoxetine requires several weeks before full therapeutic benefits become evident for the patient, unlike stimulant medications that often produce effects within hours. Several modifiable factors that should also be addressed to optimize Daniel's treatment outcomes are his poor sleep quality. It contributes to impaired concentration, reduced executive functioning, and emotional distress. Improving sleep hygiene by establishing a consistent bedtime routine, limiting caffeine consumption later in the day, and reducing evening screen time, and also practicing relaxational techniques may significantly improve daytime functioning. Occupational stress is another modifiable factor that should be addressed. This can be addressed through behavioral interventions such as cognitive behavioral therapy, stress management strategies, organizational skill training, and time management techniques. Medication adherence should also be emphasized because inconsistent use of adamoxetine may delay therapeutic response and reduce treatment effectiveness. Daniel has Daniel also has several non-modifiable risk factors that influence the treatment plan as well. These include the diagnosis of ADHD and the presence of generalized anxiety disorder and the underlying neurobiological mechanisms contributing to both of these conditions. Although these factors cannot be changed, recognizing their influence allows clinicians to individualize treatment plans and establish realistic expectations regarding symptom improvement. Careful assessment of functional impairment, ongoing symptom monitoring, and collaborative decision making remains essential components of long-term management for Daniel. I would not recommend initiating stimulant therapy with amphetamine or methylphenyldate as Daniel's first pharmacologic option. Although stimulant medications remain the most effective treatment for many individuals with ADHD, they are not without limitations. Their sympathomemetic effects may exacerbate existing anxiety symptoms, increase anxiety, and increase insomnia, elevate blood pressure and heart rate, and it can also contribute to greater emotional distress in susceptible patients. Given Daniel's history of excessive worry and persistent sleep disturbances, introducing a stimulate could complicate management of his anxiety and reduce overall quality of life. While stimulant therapy could certainly be reconsidered in the future if atamoxetine proves ineffective, beginning treatment with a non-stimulant represents, I'm sorry, beginning treatment with a non-stimulant represents a more cautious and individualized approach that aligns with patient-centered care at this juncture for Daniel. Successful treatment should also extend beyond medication. We should also be combining this with pharmacotherapy, psychoeducation, cognitive behavioral therapy, workplace organizational strategies, regular physical activity, and healthy sleep practices. All of these things can together provide the greatest opportunity for sustained improvement in attention, excessive functioning, and overall quality of life. As psychiatric mental health nurse practitioners, our responsibility is not simply to prescribe medications, but to develop comprehensive treatment plans that address each patient's biological, psychological, and social needs as well. In conclusion, I strongly support initiating atomoxetine for Daniel Kim. His cormabid generalized anxiety disorder, ongoing treatment with Certiline, absence of substance use history, and significant occupational impairment make atomoxetine the most appropriate initial medication choice. It's demonstrated efficacy in adults, ADHD, a favorable safety profile in patients with anxiety, lack of abuse potential, and compatibility with individualized treatment planning outweigh the potential benefits of initiating stimulant therapy in this clinical scenario. Through careful monitoring, patient education, and integration of behavioral interventions, Adamoxetine offers Daniels the best opportunity to improve attention, maintain anxiety control, and restore occupational functioning. Thank you very much.